Prevention of type 2 diabetes: A new public health challenge;Prévention du diabète de type 2: Un nouveau défi de santé publique

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 383-390

  Scheen, A J ^a,b   Giet, D ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Diabetes mellitus; Impaired glucose tolerance; Obesity; Prevention

Indexed keywords

ACARBOSE; GLUCOSE; METFORMIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ANAMNESIS; DIET; EXERCISE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PUBLIC HEALTH; REVIEW; RISK FACTOR;

DIABETES MELLITUS, TYPE 1; DIET; EXERCISE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OBESITY; PUBLIC HEALTH; RISK FACTORS; WEIGHT LOSS;

EID: 21744453324     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Lefèbvre PJ.- Le diabète hier, aujourd'hui et demain. L'action de la Fédération Internationale du Diabète. Rev Med Liège, 2005, 60, 273-277.
2. WHO Study Group.- Prevention of diabetes mellitus: report of WHO study group. WHO Tech Rep Ser, 1994, 844, 1-100.
3. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases.- The prevention or delay of type 2 diabetes. Diabetes Care, 2002, 25, 742-749.
4. Schulze MB, Hu FB.- Primary prevention of diabetes: what can be done and how much can be prevented? Annu Rev Public Health, 2005, 26, 445-467.
5. Scheen AJ, Paquot N, Jandrain B.- Comment j'explore... le risque d'un patient d'évoluer vers un diabète de type 2. Rev Med Liège, 2002, 57, 113-115.
6. Scheen AJ, Letiexhe MR, Ernest Ph.- Prévention du diabète de type 2: style de vie ou médicaments? Rev Med Liège, 2003, 58, 206-210.
7. Scheen AJ, Van Gaal LF, Brohet C, et al.- Belgian Evaluation of Screening and Treatment of high risk patients based on waist and age (BEST): focus on diabetes mellitus and metabolic syndrome (Abstract). Diabetes, 2005, 54 (Suppl), in press.
8. Scheen AJ.- Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 2004, 64, 2537-2565.
9. Luyckx FH, Castillo MJ.- Apport de la biologie clinique dans la mise au point et le suivi d'un patient diabétique. Rev Med Liège, 2005, 60, 590-593.
10. de Veght F, Dekker JM, Jager A, et al.- Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA, 2001, 285, 2109-2113.
11. Lorenzo C, Okoloise M, Williams K, et al.- The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care, 2003, 26, 3153-3159.
12. Scheen AJ, Van Gaal LF.- Le diabète de type 2 au coeur du syndrome métabolique: plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
13. American Diabetes Association. Position Statement.- Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care, 2003, 26 (Suppl 1), S51-61.
14. Padwal R, Majumdar SR, Johnson JA, et al.- A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care, 2005, 28, 736-744.
15. Freemark M.- Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J Clin Endocrinol Metab, 2003, 88, 3-13.
16. Rorive M, Letiexhe MR, Scheen AJ, Ziegler O.- Obésité et diabète de type 2. Rev Med Liège, 2005, 60, 374-382.
17. Paquot N.- Le régime alimentaire chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 391-394.
18. Tuomilehto J, Lindström J, Ericksson JG, et al for the Finnish Diabetes Prevention Study Group.- Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med, 2001, 344, 1343-1350.
19. Diabetes Prevention Program Research Group.- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
20. Magis D, Geronooz I, Scheen AJ.- Tabagisme, insulinorésistance et diabète de type 2. Rev Med Liège, 2002, 57, 575-581.
21. Magis D, Jandrain BJ, Scheen AJ.- Alcool, sensibilité à l'insuline et diabète sucré. Rev Med Liège, 2003, 58, 501-507.
22. Koppes LLJ, Dekker JM, Hendriks HFJ, et al.- Moderate alcohol consumption lowers the risk of type 2 diabetes. A meta-analysis of prospective observational studies. Diabetes Care, 2005, 28, 719-725.
23. Salazar-Martinez E, Willett WC, Ascherio A, et al.- Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med, 2004, 140, 1-8.
24. Tuomilehto J, Hu G, Bidel S, et al.- Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA, 2004, 291, 1213-1219.
25. Chiasson J-L, Josse RG, Gomis R, et al for the STOP-NIDDM Trial Research Group.- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 2002, 359, 2072-2077.
26. Scheen AJ.- Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs, 2003, 63, 933-951.
27. Buchanan TA, Xiang AH, Peters RK, et al.- Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 2002, 51, 2796-2803.
28. Keating GM, Jarvis B.- Orlistat. In the prevention and treatment of type 2 diabetes mellitus. Drugs, 2001, 61, 2107-2119.
29. Scheen AJ, Ernest Ph.- Antiobesity treatment in type 2 diabetes: results of clinical trials with orlistat and sibutramine. Diab Metab, 2002, 28, 437-445.
30. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L.- Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. A randomised study of orlistat as an adjunct to lifestyle for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27, 155-161.
31. Van Gaal LF, Pfeiffer FW- The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord, 2001, 25 (Suppl 4), S24-28.
32. Van Gaal LF, Rissanen AM, Scheen AJ, et al.- Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397.
33. Scheen AJ.- Prévention de l'apparition du diabète de type 2 par l'inhibition du système rénine-angiotensine. Rev Med Liège, 2002, 57, 449-452.
34. Scheen AJ.- Réduction comparable des nouveaux cas de diabète de type 2 sous sartan et sous inhibiteurs de l'enzyme de conversion de l'angiotensine: comparaison des méta-analyses des essais prospectifs randomisés. Rev Med Liège, 2005, 60, 424-428.
35. Wallemacq C, Van Gaal LF, Scheen AJ.- Le coût du diabète de type 2: résumé de l'enquête européen ne CODE-2 et analyse de la situation en Belgique. Rev Med Liège, 2005, 60, 278-284.
36. Scheen AJ.- Preventing, delaying or masking type 2 diabetes with metformin in the Diabetes Prevention Program? (Letter). Diabetes Care, 2003, 26, 2701.